{"id":"n_bc5l5lkjhx5mouu6dopa","seq":10983289,"kind":"article","title":"Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products","url":"https://laotiantimes.com/2026/11/14/zai-lab-announces-first-time-inclusion-of-karxt-and-vyvgart-hytrulo-in-chinas-2026-national-reimbursement-drug-list-expanding-access-to-key-growth-products","summary":"SHANGHAI and CAMBRIDGE, Mass, Nov. 14, 2026 /PRNewswire/ — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country’s 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for […]","published":"2026-11-14T05:38:00Z","seen":"2026-11-14T07:08:00Z","lang":"en","country":"LA","source":{"id":"kite-laotiantimes-com-d879ae","name":"laotiantimes.com","domain":"laotiantimes.com"},"via":"kite-laotiantimes-com-d879ae","topics":["asia","cision pr newswire"],"authors":["Advertorial Desk"],"story":"st_5a6wtupcrldpvuc3ufkq","category":"economy-business","category_p":0.57,"sentiment":"neutral","tone":0.36,"political":0.11}